REGINA and TORONTO, July 12, 2017 /CNW/ - Class action lawyer Tony Merchant, Q.C. announced today on behalf of Merchant Law Group LLP: "Our law offices have launched class actions against the manufacturers of certain Proton Pump Inhibitors (PPIs) regarding the risks being caused to patients from using these drugs."
"Millions of Canadians take PPIs drugs each year to reduce heartburn and other conditions, but the undisclosed risks are far too high." said Mr. Merchant.
US medical research has found (including a study http://bmjopen.bmj.com/content/7/6/e015735#T2 by medical researchers at Washington University School of Medicine) that long-term use of these drugs can be linked to a patient's shortened lifespan.
The Canada-wide PPIs class action litigation has been filed this week with the Superior Court of Ontario, the Superior Court of Quebec, and the Saskatchewan Court of Queen's Bench.
Copies of the PPIs Statements of Claim are available to the media, upon request.
The PPIs class of drugs includes Omeprazole (Prilosec or Losec), Esomeprazole (Nexium), and Lansoprazole (Prevacid), which are some of the most widely prescribed drugs in Canada [see page 11 http://www.merchantlaw.com/stats].
Any Canadian residents wanting more information concerning the Proton Pump Inhibitors class action litigation may provide their contact information at http://www.merchantlaw.com/class-actions/current-class-actions/nexium-losec-prevacid or contact our law offices. Merchant Law Group LLP operates ten law offices across Canada and is well known for pursuing class action lawsuits in Canada.
SOURCE Merchant Law Group
For further information: To arrange for media comment on today's announcement, please call Anthony Merchant, Q.C. directly in Toronto at 1-888-766-0539 or email email@example.com; For French media inquiries, please contact MLG's Montréal office at 1-514-248-7777.